These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28711549)

  • 1. A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
    Di Filippo M; Vokaer B; Seidah NG
    J Clin Lipidol; 2017; 11(4):1101-1105. PubMed ID: 28711549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fat accumulation is associated with circulating PCSK9.
    Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
    Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study.
    Eshraghian A; Moasser E; Azarpira N; Fattahi MR; Nikeghbalian S; Malek-Hosseini SA; Geramizadeh B
    BMC Gastroenterol; 2021 Dec; 21(1):458. PubMed ID: 34876018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
    Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
    Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia.
    Rimbert A; Vanhoye X; Coulibaly D; Marrec M; Pichelin M; Charrière S; Peretti N; Valéro R; Wargny M; Carrié A; Lindenbaum P; Deleuze JF; Genin E; Redon R; Rollat-Farnier PA; Goxe D; Degraef G; Marmontel O; Divry E; Bigot-Corbel E; Moulin P; Cariou B; Di Filippo M
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e63-e71. PubMed ID: 33207932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD.
    Grimaudo S; Bartesaghi S; Rametta R; Marra F; Margherita Mancina R; Pihlajamäki J; Kakol-Palm D; Andréasson AC; Dongiovanni P; Ludovica Fracanzani A; Lori G; Männistö V; Pellegrini G; Bohlooly-Y M; Pennisi G; Maria Pipitone R; Spagnuolo R; Craxì A; Lindén D; Valenti L; Romeo S; Petta S
    Liver Int; 2021 Feb; 41(2):321-332. PubMed ID: 33091218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol.
    Ioannou GN; Lee SP; Linsley PS; Gersuk V; Yeh MM; Chen YY; Peng YJ; Dutta M; Mascarinas G; Molla B; Cui JY; Savard C
    Hepatol Commun; 2022 Apr; 6(4):780-794. PubMed ID: 34816633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.
    Mbikay M; Mayne J; Seidah NG; Chrétien M
    Med Hypotheses; 2007; 69(5):1010-7. PubMed ID: 17502126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways.
    Huang P; Ran J; Zhu W; Dai W; Tang Y; Lian P; Huang X; Li R
    FASEB J; 2024 Feb; 38(4):e23464. PubMed ID: 38358343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A promising therapy for fatty liver disease: PCSK9 inhibitors.
    Han L; Wu L; Yin Q; Li L; Zheng X; Du S; Huang X; Bai L; Wang Y; Bian Y
    Phytomedicine; 2024 Jun; 128():155505. PubMed ID: 38547616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
    Baragetti A; Balzarotti G; Grigore L; Pellegatta F; Guerrini U; Pisano G; Fracanzani AL; Fargion S; Norata GD; Catapano AL
    Eur J Prev Cardiol; 2017 Nov; 24(17):1870-1877. PubMed ID: 28758421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The common PNPLA3 variant p.I148M is associated with liver fat contents as quantified by controlled attenuation parameter (CAP).
    Arslanow A; Stokes CS; Weber SN; Grünhage F; Lammert F; Krawczyk M
    Liver Int; 2016 Mar; 36(3):418-26. PubMed ID: 26264356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.
    Abifadel M; Rabès JP; Devillers M; Munnich A; Erlich D; Junien C; Varret M; Boileau C
    Hum Mutat; 2009 Apr; 30(4):520-9. PubMed ID: 19191301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
    Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
    Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene.
    Tada H; Okada H; Nomura A; Nohara A; Takamura M; Kawashiri MA
    Intern Med; 2020; 59(6):783-787. PubMed ID: 32173689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.